vobarilizumab   

GtoPdb Ligand ID: 8363

Synonyms: ALX-0061
Compound class: Antibody
Comment: Vobarilizumab is an investigational bispecific peptide NanobodyTM which binds soluble IL-6R and human albumin (albumin binding being utilised as a half-life extension methodology). Design and production of ALX-0061 is described in patent US8748581 [2]. Vobarilizumab is being developed for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Preclinical information is published in [6].
The exact NanobodyTM structure being used as ALX-0061 was not revealed in the covering patent [2], but has been disclosed in the INN submission. Annotated peptide sequences for this therapeutic are available from its IMGT/mAb-DB record.
References
1. A-González N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim. Biophys. Acta, 1812 (8): 982-94. [PMID:21193033]
2. Beirnaert EAA, Ververken CJN, Kolkman JA, Van Roy M. (2014)
Anti-IL-6R polypeptides and pharmaceutical compositions thereof.
Patent number: US8748581. Assignee: Ablynx N.V.. Priority date: 10/04/2009. Publication date: 10/06/2014.
3. Hirohata S, Kikuchi H. (2012)
Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet's disease.
Intern. Med., 51 (24): 3359-65. [PMID:23257520]
4. Kristiansen OP, Mandrup-Poulsen T. (2005)
Interleukin-6 and diabetes: the good, the bad, or the indifferent?.
Diabetes, 54 Suppl 2: S114-24. [PMID:16306329]
5. Tackey E, Lipsky PE, Illei GG. (2004)
Rationale for interleukin-6 blockade in systemic lupus erythematosus.
Lupus, 13 (5): 339-43. [PMID:15230289]
6. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015)
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Arthritis Res. Ther., 17: 135. [PMID:25994180]